UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
/X/ Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 for the quarterly period ended
September 30, 2001
or
/ / Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 for the transition period
from ____ to _____.
Commission File No. 000-30109
LUMINEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 74-2747608 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 12212 Technology Blvd., Austin, Texas 78727 (Address of principal executive offices) (Zip Code) (512) 219-8020 (Registrant's telephone number, including area code) _________________ |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /X/ No / /
There were 28,676,435 shares of the Company's Common Stock, par value $.001 per share, outstanding on November 6, 2001.
INDEX
Page ---- PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of September 30, 2001 and December 31, 2000............................... 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2001 and 2000.. 2 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2001 and 2000............ 3 Notes to Condensed Consolidated Financial Statements.......... 4 Independent Accountants' Review Report........................ 6 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations................................ 7 Factors That May Affect Future Results........................ 11 Item 3. Quantitative and Qualitative Disclosure about Market Risk..... 17 PART II. OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K.............................. 18 SIGNATURES.............................................................. 19 |
PART I
ITEM 1. FINANCIAL STATEMENTS
LUMINEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
ASSETS
September 30, December 31, 2001 2000 ------------- ------------- (unaudited) Current assets: Cash and cash equivalents............................................... $ 36,499 $ 7,106 Short-term investments.................................................. 19,611 66,521 Accounts receivable, net................................................ 6,743 3,085 Inventories............................................................. 7,564 2,408 Other................................................................... 642 1,739 ------------- ------------- Total current assets................................................ 71,059 80,859 Property and equipment, net .................................................. 3,572 2,770 Intangible assets, net ....................................................... 596 - Notes receivable - related parties............................................ 439 39 ------------- ------------- Total assets........................................................ $ 75,666 $ 83,668 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable........................................................ $ 2,942 $ 2,741 Accrued liabilities..................................................... 1,650 673 Deferred revenue........................................................ 679 666 ------------- ------------- Total current liabilities........................................... 5,271 4,080 Long-term deferred revenue ................................................... 291 900 ------------- ------------- Total liabilities................................................... 5,562 4,980 Stockholders' equity: Common stock............................................................ 29 28 Additional paid-in capital.............................................. 118,279 115,651 Deferred stock compensation............................................. (803) (1,529) Accumulated deficit..................................................... (47,401) (35,462) ------------- ------------- Total stockholders' equity.......................................... 70,104 78,688 ------------- ------------- Total liabilities and stockholders' equity.......................... $ 75,666 $ 83,668 ============= ============= |
See Independent Accountants' Review Report.
LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three Months Ended Nine Months Ended September 30, September 30, ----------------------- ----------------------- 2001 2000 2001 2000 -------- -------- -------- -------- (unaudited) (unaudited) Revenue: Product..................................... $ 6,188 $ 2,190 $ 14,272 $ 4,974 Grant....................................... - 125 492 125 -------- -------- -------- -------- Total revenue.......................... 6,188 2,315 14,764 5,099 Cost of product revenue..................... 4,182 1,416 10,710 3,124 -------- -------- -------- -------- Gross profit........................... 2,006 899 4,054 1,975 Operating expenses: Research and development ................... 1,857 2,284 6,495 6,025 Selling, general and administrative ........ 4,355 2,656 11,939 7,559 -------- -------- -------- -------- Total operating expenses............... 6,212 4,940 18,434 13,584 Loss from operations ............................ (4,206) (4,041) (14,380) (11,609) Interest income ............................ 585 1,311 2,441 2,624 -------- -------- -------- -------- Net loss......................................... $ (3,621) $ (2,730) $(11,939) $ (8,985) ======== ======== ======== ======== Net loss per share, basic and diluted ........... $ (0.13) $ (0.10) $ (0.42) $ (0.40) ======== ======== ======== ======== Shares used in computing net loss per share, basic and diluted ............... 28,435 27,197 28,199 22,553 |
See Independent Accountants' Review Report.
LUMINEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Nine Months Ended September 30, ------------------------- 2001 2000 -------- -------- (unaudited) Operating activities: Net loss................................................ $(11,939) $ (8,985) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization....................... 1,156 666 Stock compensation.................................. 706 2,273 Changes in operating assets and liabilities: Accounts receivable................................. (3,658) (743) Inventories ........................................ (5,156) (574) Other............................................... 1,097 (1,382) Accounts payable.................................... 201 751 Accrued liabilities ................................ 977 239 Deferred revenue ................................... (596) 741 -------- -------- Net cash used in operating activities ........................ (17,212) (7,014) -------- -------- Investing activities: Net maturities (purchases) of short-term investments.... 46,910 (56,390) Purchase of property and equipment...................... (1,954) (1,829) Notes receivable - related parties...................... (400) (74) Acquired technology rights.............................. (600) - -------- -------- Net cash provided by (used in) investing activities .......... 43,956 (58,293) -------- -------- Financing activities: Proceeds from issuance of common stock.................. 2,649 78,008 Stock issuance costs.................................... - (1,242) -------- -------- Net cash provided by financing activities .................... 2,649 76,766 -------- -------- Increase in cash and cash equivalents ........................ 29,393 11,459 Cash and cash equivalents, beginning of period ............... 7,106 4,083 -------- -------- Cash and cash equivalents, end of period ..................... $ 36,499 $ 15,542 ======== ======== Supplemental disclosure of noncash activities: Conversion of preferred stock........................... $ - $ 28,946 Accrued stock issuance cost............................. $ - $ 18 |
See Independent Accountants' Review Report.
LUMINEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1--BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the "Company") in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. The consolidated financial statements include the accounts of Luminex Corporation and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2001 are not necessarily indicative of the results that may be expected for the year ending December 31, 2001. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2000.
NOTE 2--INVENTORIES
Inventories consisted of the following (in thousands):
September 30, December 31, 2001 2000 ------------- ------------ Parts and supplies............................ $ 5,381 $ 2,002 Work-in-progress and finished goods........... 2,183 406 ------------- ------------ $ 7,564 $ 2,408 ============= ============ |
NOTE 3--INTANGIBLE ASSETS, NET
In March 2001, the Company entered into an agreement that provides the Company with a license to commercialize products incorporating certain patented technology. Under the terms of the agreement, the Company made $600,000 in milestone payments through September 30, 2001, and has agreed to make additional payments of $400,000 in the aggregate upon the achievement of additional milestones. In addition, the Company will make royalty payments based on sales of the developed products incorporating the licensed technology. The costs of the technology rights acquired were capitalized and are being amortized on a straight-line basis over their estimated useful life.
NOTE 4--NOTES RECEIVABLE - RELATED PARTIES
Notes receivable - related parties at September 30, 2001, consisted of notes from two officers of the Company. One note was executed in connection with the relocation and employment of an officer. This note had an original principal amount of $400,000, and is secured by mortgaged real property. The promissory note is non-interest bearing and is due on the earlier of (i) the termination of the officer or (ii) May 9, 2011. Contingent upon the continued employment of the officer, beginning October 2, 2001, the principal amount will be forgiven to the extent of $50,000 each year until October 2, 2004, for a total possible reduction of $200,000.
NOTE 5--NET LOSS PER SHARE
In accordance with Statement of Financial Accounting Standards No. 128, Earnings Per Share, basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common shares outstanding during the period.
LUMINEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(unaudited)
The Company has excluded all potentially dilutive securities such as convertible preferred stock, outstanding stock options and outstanding warrants to purchase common stock from the calculation of diluted loss per common share because such securities are anti-dilutive due to the Company's net loss for all periods presented. The total shares excluded from the calculations of diluted net loss per share, prior to application of the treasury stock method for options and warrants, were 3,861,440 and 3,980,149 for the three and nine months ended September 30, 2001, respectively, and 2,902,082 and 12,229,099 for the three and nine months ended September 30, 2000, respectively.
Pro forma net loss per share amounts have been computed as described above and give effect to common equivalent shares arising from preferred stock that automatically converted upon the April 3, 2000 closing of the Company's initial public offering as if the preferred shares had converted at the original date of issuance.
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share (in thousands, except per share amounts):
Three Months Ended Nine Months Ended September 30, September 30, ------------------------ ----------------------- 2001 2000 2001 2000 -------- --------- -------- -------- Basic and diluted: Net loss ............................................................ $ (3,621) $ (2,730) $(11,939) $(8,985) Weighted average shares of common stock outstanding.................. 28,435 27,197 28,199 22,553 Net loss per share, basic and diluted ............................... $ (0.13) $ (0.10) $ (0.42) $ (0.40) ======== ======== ======== ======= Net loss per share, basic and diluted: Shares used above............................................... 28,435 27,197 28,199 22,553 Add: Pro forma adjustment to reflect weighted average effect of assumed conversion of preferred stock... - - - 2,880 -------- --------- -------- ------- Shares used in computing basic and diluted pro forma net loss per share, basic and diluted pro forma.................... 28,435 27,197 28,199 25,433 Net loss per share, basic and diluted pro forma................. $ (0.13) $ (0.10) $ (0.42) $ (0.35) ======== ======== ======== ======= |
NOTE 6--STOCKHOLDERS' RIGHTS PLAN
On June 20, 2001, the Company's Board of Directors declared a dividend of one right for each outstanding share of the Company's common stock to stockholders of record at the close of business on July 2, 2001. Each right entitles the registered holder, upon the occurrence of certain triggering events, to purchase from the Company one one-hundredth of a share of Series A Junior Participating Preferred Stock, par value $.001 per share, at a purchase price of $100 per fractional share, subject to adjustment.
INDEPENDENT ACCOUNTANTS' REVIEW REPORT
To The Board of Directors of
Luminex Corporation
We have reviewed the accompanying condensed consolidated balance sheet of Luminex Corporation as of September 30, 2001, the related condensed consolidated statements of operations for the three and nine months ended September 30, 2001 and 2000, and the related condensed consolidated statements of cash flows for the nine months ended September 30, 2001 and 2000. These financial statements are the responsibility of the Company's management.
We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data, and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States, which will be performed for the full year with the objective of expressing an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements at September 30, 2001, and for the three and nine month periods ended September 30, 2001 and 2000, for them to be in conformity with accounting principles generally accepted in the United States.
We have previously audited in accordance with auditing standards generally accepted in the United States, the consolidated balance sheet of Luminex Corporation as of December 31, 2000, and the related consolidated statements of operations, stockholders' equity, and cash flows for the year then ended [not presented herein] and in our report dated January 26, 2001, we expressed an unqualified opinion on those financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2000, is fairly stated, in all material aspects, in relation to the consolidated balance sheet from which it has been derived.
/s/ Ernst & Young LLP Austin, Texas October 18, 2001 |
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following information should be read in conjunction with the condensed consolidated financial statements and the accompanying notes included in Item 1 of this report, our Form 10-K for the year ended December 31, 2000 and "Factors That May Affect Future Results" in this report.
Safe Harbor Cautionary Statement
All statements in this report that do not discuss past results are forward- looking statements. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "will" and similar expressions identify forward- looking statements. All statements which address our outlook for our businesses and their respective markets, such as projections of future performance, statements of management's plans and objectives, forecasts of market trends and other matters are forward-looking statements. It is important to note that our actual results or performance could differ materially from those projected in such forward-looking statements. Forward-looking statements are based on management's current expectations and are therefore subject to certain risks and uncertainties, including those discussed under the section titled "Factors That May Affect Future Results" included in this report. Specific uncertainties which could cause our actual results to differ materially from those projected include risks and uncertainties relating to market demand for and acceptance of our products, our dependence on strategic partners for development and distribution of products, competition, our ability to scale-up manufacturing operations, potential shortages of components and the timing and content of regulatory approvals and rulings. We expressly disclaim any intent, obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained in this report to reflect any change in our expectations with regard to such statements or any change in events, conditions or circumstances on which any such statements are based.
Overview
Since inception, we have incurred significant losses and, as of September 30, 2001, we had an accumulated deficit of $47.4 million. Our limited operating history makes accurate predictions of future operations difficult. Moreover, we anticipate that our quarterly results of operations will fluctuate for the foreseeable future due to several factors, including the rate of market acceptance of current and new products, the timing of the introduction by our strategic partners of commercial products based on our technology, the timing of regulatory approvals, our ability to scale up manufacturing operations and avoid component shortages, the introduction of new products by our competitors, the timing and extent of our research and development efforts and the timing of significant orders.
Our ability to achieve sustained profitability will depend upon our ability to continue to enter into strategic partnerships with companies that will develop and market products incorporating our technology and market and distribute our systems and consumables. Certain of our strategic partners develop application-specific bioassay kits for use on our systems that they sell to their customers generating royalties for us. Other strategic partners perform testing services for third parties using our technology that also result in royalties for us. Some strategic partners buy our products and then resell those products to their customers. Through September 30, 2001, we have entered into strategic partnerships with 32 companies.
Revenue on sales of our products is recognized when persuasive evidence of an agreement exists, delivery has occurred, the fee is fixed and determinable, and collectibility is probable. Generally, these criteria are met at the time our product is shipped. We expect that our systems sales will generate a recurring revenue stream from the sale of consumable products. In addition, we expect to generate royalty revenue from some of our strategic partners as they sell products incorporating our technology or provide testing services to third parties using our technology.
Cost of product revenue consists of direct and indirect instrument and reagent manufacturing, quality control, training, field service, customer service and warranty costs. Our operating expenses have consisted primarily of costs incurred in research and development, manufacturing scale-up and business development and from general and administrative costs associated with our operations. We expect our research and development expenses for the next quarter to approximate our third quarter 2001 spending level. Our selling and marketing expenses will increase as we continue to commercialize our products, and general and administrative expenses will increase as we add personnel and expand our facilities.
Deferred stock compensation represents the difference between the deemed fair value of our common stock and the exercise price of options or warrants or the fair market value of restricted stock grants. For options and restricted stock granted to employees and directors, this difference is calculated as of the grant date and amortized ratably over the vesting period. For options or warrants granted to consultants, the difference is recognized as of the vesting date with adjustments made to the recognized deferred compensation amount up and until that time based on the market value of our common stock. As a result of stock options, warrants and restricted stock grants, we recorded $228,000 and $200,000 in deferred stock compensation expense for the three months ended September 30, 2001 and 2000, respectively, and $706,000 and $2.3 million in deferred stock compensation expense for the nine months ended September 30, 2001 and 2000, respectively. Total unamortized deferred stock compensation as of September 30, 2001 was $803,000.
Total deferred revenue as of September 30, 2001 was $970,000, and consisted
of (i) payments received for sales to customers with rights of return that had
not yet expired, (ii) upfront payments from strategic partners to be used for
the purchase of products or to be applied towards future royalty payments and
(iii) payments received for service, maintenance and training revenue not yet
earned. Upfront payments from our strategic partners are nonrefundable and will
be recognized as revenue as our strategic partners purchase products or apply
such amounts against royalty payments.
Results of Operations
Three Months Ended September 30, 2001 Compared to Three Months Ended September 30, 2000
Revenue. Product revenue increased 183% to $6.2 million for the three months ended September 30, 2001. The increase was primarily attributable to increased system sales, as well as increased consumable sales. During the third quarter of 2001, we placed 175 Luminex 100 systems, 1 HTS system, 149 Luminex XY Platforms and 135 SD units compared with 90 Luminex 100 systems, 49 XY Platforms and no HTS systems or SD units placed in the third quarter of 2000. Consumable sales increased by 430% to $1.5 million, which is attributable to the increase in the installed base of Luminex systems and purchases by strategic partners for use in kit manufacturing and development.
After being temporarily suspended in September 1999, our government grant was reinstated July 1, 2000 with a new joint venture partner. On July 1, 2001, the reinstated grant was suspended due to the withdrawal of the new joint venture partner. As a result, we did not recognize any grant revenue in the third quarter of 2001 and do not expect to realize any further grant revenue in future periods.
A breakdown of revenue for the three months ended September 30, 2001 and 2000 is as follows (in thousands):
Three Months Ended September 30, ------------------ 2001 2000 ------ ------ System sales............ $4,420 $1,883 Consumable sales......... 1,457 275 Grant revenue............ - 125 Other revenue............ 311 32 ------ ------ Total revenue...... $6,188 $2,315 ====== ====== |
Gross Profit. Gross profit increased by 123% to $2.0 million for the three months ended September 30, 2001. Gross margin (gross profit as a percentage of total revenue) decreased from 39% for the three months ended September 30, 2000 to 32% for the three months ended September 30, 2001. The decrease in gross margin was attributable to the loss of grant revenue, increased indirect personnel costs and indirect overhead costs, which were partially offset by an increase in the sales of consumables, which have a higher gross margin than system sales.
Research and Development Expense. Research and development expenses decreased 19% to $1.9 million for the three months ended September 30, 2001. The decrease was attributable to several factors, including decreased consumption of parts and supplies of $578,000 and decreased stock compensation expense of $83,000, which was offset by increased personnel cost of $129,000 due to an increased number of employees. The decrease in consumption of parts and supplies was attributable to the completion of certain projects.
Selling, General and Administrative Expense. Selling, general and
administrative expenses increased by 64% to $4.4 million for the three months
ended September 30, 2001. The increase was attributable to several factors,
including (i) increased personnel costs of $891,000 due to growth in employment,
(ii) increased professional expenses of $251,000 including marketing activities,
(iii) increased corporate insurance costs of $220,000, (iv) increased non-cash
stock compensation expense of $118,000 and (v) increased travel and
entertainment costs of $105,000 incurred to support business development
activities.
Interest Income. Interest income decreased by 33% to $585 for the three months ended September 30, 2001. The decrease was attributable to a decrease in the average cash and short-term investment balances, resulting from increased operating expenses, and a lower yield on the investment balances.
Nine Months Ended September 30, 2001 Compared to Nine Months Ended September 30, 2000
Revenue. Product revenue increased 187% to $14.3 million for the nine months ended September 30, 2001. The increase was primarily attributable to increased system sales, as well as increased consumable sales. During the first nine months of 2001, we placed 464 Luminex 100 systems, 3 HTS systems, 346 Luminex XY Platforms and 250 SD units compared with 177 Luminex 100 systems, 158 XY Platforms and no HTS systems or SD units placed in the first nine months of 2000. Consumable sales increased by 351% to $2.8 million, which is attributable to the increase in the installed base of Luminex systems and purchases by strategic partners for use in kit manufacturing and development.
After being temporarily suspended in September of 1999, the original government grant was reinstated July 1, 2000 with a new joint venture partner. On July 1, 2001, the reinstated grant was suspended due to the withdrawal of the new joint venture partner. As a result, we do not expect to realize any further grant revenue in future periods.
A breakdown of revenue for the nine months ended September 30, 2001 and 2000 is as follows (in thousands):
Nine Months Ended September 30, ----------------------- 2001 2000 -------- -------- System sales.................... $ 10,707 $ 4,246 Consumable sales................ 2,796 620 Grant revenue................... 492 125 Other revenue................... 769 108 -------- -------- Total revenue............. $ 14,764 $ 5,099 ======== ======== |
Gross Profit. Gross profit increased by 105% to $4.1 million for the nine months ended September 30, 2001. Gross margin (gross profit as a percentage of total revenue) decreased from 39% for the nine months ended September 30, 2000 to 27% for the nine months ended September 30, 2001. The decrease in gross margin was attributable to several factors including (i) lower average selling prices of our systems, resulting from discounted sales to early adopting strategic partners, (ii) increased indirect personnel costs and (iii) increased indirect overhead costs. This increase was partially offset by a favorable change in product mix.
Research and Development Expense. Research and development expenses increased 8% to $6.5 million for the nine months ended September 30, 2001. The increase was primarily attributable to an increased personnel costs of $709,000 due to an increased number of employees. This increase was partially offset by a $534,000 reduction of non-cash stock compensation expense.
Selling, General and Administrative Expense. Selling, general and administrative expenses increased by 58% to $12.0 million for the nine months ended September 30, 2001. The increase was attributable to several factors, including (i) increased personnel costs of $2.5 million due to growth in employment, (ii) increased corporate insurance costs of $962,000, (iii) increased professional expenses of $926,000 and (iv) increased sales and marketing expenses including travel and entertainment of $743,000 incurred to support business development activities. These increases were partially offset by a $1.0 million reduction of non-cash stock compensation expenses.
Interest Income. Interest income decreased by 7% to $2.4 million for the nine months ended September 30, 2001. The decrease was attributable to a decrease in the average cash and short-term investment balances, and a lower yield on investment balances.
Liquidity and Capital Resources
We have funded our operations to date primarily through the issuance of equity securities. At September 30, 2001, we held cash, cash equivalents and short-term investments of $56.1 million and had working capital of $65.8 million. At December 31, 2000, we held cash, cash equivalents and short-term investments of $73.6 million. Our cash reserves are held directly or indirectly in a variety of short-term, interest-bearing instruments, including obligations of the United States government or agencies thereof and U.S. corporate debt securities.
Cash used in operations was $17.2 million for the nine months ended September 30, 2001, compared with $7.0 million for the nine months ended September 30, 2000. Purchases of property and equipment for the nine months ended September 30, 2001 totaled $2.0 million, compared with $1.8 million for the nine months ended September 30, 2000.
Our future capital requirements will depend on a number of factors, including our success in developing and expanding markets for our products, payments under possible future strategic arrangements, continued progress of our research and development of potential products, the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the need to acquire licenses to new technology and the status of competitive products. We believe that our existing cash, cash equivalents and short term-investments will be sufficient to fund our operating expenses and capital equipment requirements through at least September 30, 2002.
We have no credit facility or other committed sources of capital. To the extent capital resources are insufficient to meet future capital requirements, we will have to raise additional funds. There can be no assurance that additional funds will be available on favorable terms, if at all. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of those securities could result in dilution to our stockholders. Moreover, incurring debt financing could result in a substantial portion of our operating cash flow being dedicated to the payment of principal and interest on such indebtedness, could render us more vulnerable to competitive pressures and economic downturns and could impose restrictions on our operations. If adequate funds are not available, we may be required to curtail operations significantly or to obtain funds through entering into agreements on unattractive terms.
FACTORS THAT MAY AFFECT FUTURE RESULTS
If our technology and products do not become widely used in the life sciences industry, it is unlikely that we will ever become profitable.
Life sciences companies have historically conducted biological tests using a variety of technologies, including bead-based analysis. However, compared to certain other technologies, our LabMAP(TM) technology is new and relatively unproven, and the use of our technology by life sciences companies is limited. The commercial success of our technology will depend upon its widespread adoption as a method to perform bioassays. In order to be successful, we must convince potential customers to utilize our system instead of competing technologies. Market acceptance will depend on many factors, including our ability to:
. convince prospective strategic partners and customers that our technology is an attractive alternative to other technologies for pharmaceutical, research, clinical and biomedical testing and analysis;
. manufacture products in sufficient quantities with acceptable quality and at an acceptable cost; and
. place and service sufficient quantities of our products.
Because of these and other factors, our products may not gain sufficient market acceptance to achieve profitability.
Our business plan may not succeed unless we establish meaningful and successful relationships with our strategic partners.
Our strategy for the development and commercialization of our LabMAP technology is highly dependent on our ability to establish successful strategic relationships with a number of partners. Our ability to enter into agreements with additional partners depends in part on convincing them that our technology can help achieve and accelerate their goals or efforts. We will expend substantial funds and management efforts with no assurance that any additional strategic relationships will result. We cannot assure you that we will be able to negotiate additional strategic agreements in the future on acceptable terms, if at all, or that current or future partners will not pursue or develop alternative technologies either on their own or in collaboration with others. Some of the companies we are targeting as strategic partners offer products competitive with our LabMAP technology, which may hinder or prevent strategic relationships. Termination of strategic relationships, or the failure to enter into a sufficient number of additional agreements on favorable terms, could reduce sales of our products, lower margins on our products and limit the creation of market demand and acceptance.
Our business plan contemplates that a significant portion of our future revenues will come from sales of our systems and the development and sale of bioassay kits utilizing our technology by our strategic partners and from use of our technology by our strategic partners in performing services offered to third parties. We believe that our strategic partners will have economic incentives to develop and market these products, but we cannot predict future sales and royalty revenues because our existing strategic partner agreements do not include minimum purchase requirements. In addition, we do not have the right or ability to provide incentives to our strategic partners' sales personnel to sell products based on LabMAP technology or to control the timing of the release of products by our strategic partners. The amount of these revenues will depend on a variety of factors that are outside our control, including the amount and timing of resources that current and future strategic partners devote to develop and market products incorporating our technology. Further, the development and marketing of certain bioassay kits will require our strategic partners to obtain governmental approvals, which could delay or prevent their commercialization efforts. If our current or future strategic partners do not successfully develop and market products based on our technology and obtain necessary government approvals, our revenues from product sales and royalties will be significantly reduced.
The life sciences industry is highly competitive and subject to rapid technological change and we may not have the resources necessary to successfully compete.
We compete with companies in the United States and abroad that are engaged in the development and production of similar products. We will continue to face intense competition from existing competitors as well as other companies seeking to develop new technologies. Many of our competitors have access to greater financial, technical, scientific, research, marketing, sales, distribution, service and other resources than we do. These companies may develop technologies that are superior alternatives to our technologies or may be more effective at commercializing their technologies in products.
The life sciences industry is characterized by rapid and continuous technological innovation. We may need to develop new technologies for our products to remain competitive. Our present or future products could be rendered obsolete or uneconomical by technological advances by one or more of our current or future competitors. In addition, the introduction or announcement of new products by us or by others could result in a delay of or decrease in sales of existing products, as customers evaluate these new products. Our future success will depend on our ability to compete effectively against current technologies as well as to respond effectively to technological advances.
The intellectual property rights we rely upon to protect the technology underlying our products may not be adequate, which could enable third parties to use our technology or very similar technology and could reduce our ability to compete in the market.
Our success will depend on our ability to obtain, protect and enforce patents on our technology and to protect our trade secrets. Any patents we own may not afford meaningful protection for our technology and products. Others may challenge our patents and, as a result, our patents could be narrowed, invalidated or rendered unenforceable. In addition, our current and future patent applications may not result in the issuance of patents in the United States or foreign countries. Competitors may develop products similar to ours that are not covered by our patents. Further, there is a substantial backlog of patent applications at the U.S. Patent and Trademark Office, and the approval or rejection of patent applications may take several years.
We have obtained and filed a number of patents in the United States on various aspects and applications of our technology and have pending applications in certain foreign jurisdictions. In Japan, due to a procedural omission by our previous patent counsel, we are unable to obtain patent protection for our method of "real time" detection and quantification of multiple analyses from a single sample similar to the protection we have obtained in the United States, although we are pursuing patent protection in Japan for other aspects of our technology. As a result, we may not be able to prevent competitors from developing and marketing technologies similar to our LabMAP technology in Japan.
We require our employees and consultants to execute confidentiality agreements. However, we cannot guarantee that these agreements will provide us with adequate protection against improper use or disclosure of confidential information. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants or advisors have prior employment or consulting relationships. Further, others may independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets. Our failure to protect our proprietary information and techniques may inhibit or limit our ability to exclude certain competitors from the market.
In order to protect or enforce our patent rights, we may have to initiate legal proceedings against third parties, such as infringement suits or interference proceedings. These legal proceedings could be expensive, take significant time and divert management's attention from other business concerns. If we lose, we may lose the benefit of some of our intellectual property rights, the loss of which may inhibit or remove our ability to exclude certain competitors from the market. We may also provoke these third parties to assert claims against us. The patent position of companies like ours generally is highly uncertain, involves complex legal and factual questions, and has recently been the subject of much litigation. No consistent policy has emerged from the U.S. Patent and Trademark Office or the courts regarding the breadth of claims allowed or the degree of protection afforded under patents like ours.
Our success will depend partly on our ability to operate without infringing on or misappropriating the proprietary rights of others.
We may be sued for infringing on the intellectual property rights of others. In addition, we may find it necessary, if threatened, to initiate a lawsuit seeking a declaration from a court that we do not infringe the proprietary rights of others or that their rights are invalid or unenforceable. Intellectual property litigation is costly, and, even if we prevail, the cost of such litigation could affect our profitability. In addition, litigation is time consuming and could divert management attention and resources away from our business. If we do not prevail in any litigation, in addition to any damages we might have to pay, we could be required to stop the infringing activity or obtain a license. Any required license may not be available to us on acceptable terms, or at all. In addition, some licenses may be nonexclusive, and therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license or are unable to design around a patent, we may be unable to sell some of our products, which could have a material adverse affect on our business, financial condition and results of operations.
We are aware of a European patent granted to Dr. Ioannis Tripatzis, which covers certain testing agents and certain methods of their use. Dr. Tripatzis has publicly stated his belief that his patent covers aspects of our technology. This patent expires in 2004. We cannot assure you that a dispute with Dr. Tripatzis will not arise or that any dispute with him will be resolved in our favor.
We have only produced our products in limited quantities and we may experience problems in scaling up our manufacturing operations or delays or component shortages that could limit the growth of our revenue.
To date, we have produced our products in limited quantities compared to the quantities necessary to achieve projected revenues. We may not be able to produce sufficient quantities or maintain consistency between differing lots of consumables. If we encounter difficulties in scaling up our manufacturing operations due to, among other things, quality control and quality assurance and component and raw material supplies, we will likely experience reduced sales of our products, increased repair or re-engineering costs due to product returns and defects and increased expenses due to switching to alternate suppliers, any of which would reduce our revenues and gross margins.
We presently outsource certain aspects of the assembly of our systems to contract assemblers. In addition, certain key components of our product line are currently purchased from a limited number of outside sources and may only be available through a few sources. We do not have agreements with all of our suppliers. Our reliance on our suppliers and contract assemblers exposes us to risks including:
. the possibility that one or more of our suppliers or our assemblers could terminate their services at any time without penalty;
. the potential inability of our suppliers to obtain required components;
. the potential delays and expenses of seeking alternate sources of supply or manufacturing services; and
. reduced control over pricing, quality and timely delivery due to the difficulties in switching to alternate suppliers or assemblers.
Consequently, in the event that supplies of components or work performed by any of our assemblers are delayed or interrupted for any reason, our ability to produce and supply our products could be impaired.
Our bioinformatics group is subject to additional risks and uncertainties.
Our bioinformatics group seeks to identify associations among the proteins in blood that cause disease. We intend to identify these associations by testing different blood samples for a large number of protein markers. The creation of this database will be dependent on our ability to obtain a sufficient number of blood samples and related medical histories to permit the observation of these associations. These blood samples may need to include multiple
samples from persons who developed diseases over the period of time during which the samples were collected. In addition, we will need to create large panels of bioassays to test the blood samples. To the extent we are unable to obtain sufficient quantities of relevant blood samples and medical histories, or cannot develop a large panel of bioassays to test the samples, we will not be able to create the database or to produce meaningful information from it.
If we encounter difficulties in developing the bioinformatics software that will be used to analyze the database information or in maintaining the database, our ability to identify useful information from the database will be adversely affected. Our efforts to create the database and create algorithms to analyze the information that will be contained in the database have only recently begun. There can be no assurance that these efforts will be successful or lead to useful scientific information. Our ability to attract customers for any information that may be developed will be heavily dependent upon the successful completion of the database and the analyses thereof within the expected time frames. In addition, because our bioinformatics business will require manipulating and analyzing large amounts of data, we will be dependent on the continuous, effective, reliable and secure operation of our computer hardware, software, networks and related infrastructure. We expect that this database and the bioinformatics software will be complex and sophisticated, and as such, could contain data, design or software errors that could be difficult to detect and correct.
Our success will depend on our ability to attract and to retain our management and staff.
We depend on the principal members of our management and scientific staff, including our research and development, customer support, technical service and sales staff. The loss of services of any of our key members of management could delay or reduce our product development, sales and customer support efforts. In addition, recruiting and retaining qualified scientific and other personnel to perform research and development, customer support, technical service and sales work will be critical to our success. There is a shortage in our industry of qualified management and scientific personnel, and competition for these individuals is intense. There can be no assurance that we will be able to attract additional and retain existing personnel.
If we fail to comply with the extensive governmental regulations that affect our business, we could be subject to enforcement actions, injunctions and civil and criminal penalties that could delay or prevent marketing of our products.
The production, labeling, distribution and marketing of our products for some purposes and products based on our technology expected to be produced by our strategic partners are subject to governmental regulation by the Food and Drug Administration in the United States and by similar agencies in other countries. Some of our products and products based on our technology expected to be produced by our strategic partners for in vitro diagnostic purposes are subject to approval or clearance by the FDA prior to marketing for commercial use. To date, only one such approval or clearance has been obtained by our strategic partners. The process of obtaining necessary FDA clearances or approvals can be time-consuming, expensive and uncertain. Further, clearance or approval may place substantial restrictions on the indications for which the product may be marketed or to whom it may be marketed. In addition, we are also required to comply with FDA requirements relating to laser safety.
Approved or cleared products are subject to continuing FDA requirements relating to quality control and quality assurance, maintenance of records and documentation and labeling and promotion of medical devices. Our inability, or the inability of our strategic partners, to obtain required regulatory approval or clearance on a timely or acceptable basis could harm our business. In addition, failure to comply with applicable regulatory requirements could subject us or our strategic partners to enforcement action, including product seizures, recalls, withdrawal of clearances or approvals, restrictions on or injunctions against marketing our products or products based on our technology, and civil and criminal penalties.
Medical device laws and regulations are also in effect in many countries outside the United States. These range from comprehensive device approval requirements for some or all of our medical device products to requests for product data or certifications. The number and scope of these requirements are increasing. Failure to comply with applicable federal, state and foreign medical device laws and regulations may harm our business, financial condition and results of operations. We are also subject to a variety of other laws and regulations relating to, among other things, environmental protection and work place safety.
Our bioinformatics group will also be subject to various governmental regulations, which may delay or prohibit certain planned activities. Certain biological testing has raised issues regarding confidentiality and the appropriate uses of the resulting information. For example, concerns have been expressed towards insurance carriers and employers using such tests to discriminate on the basis of such information, resulting in barriers to the acceptance of such tests by consumers. This could lead to governmental authorities calling for limits on or regulation of the use of testing of the type proposed to be performed. Such regulations would likely reduce the potential markets for any products that might be developed.
If we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage.
Our business exposes us to potential product liability claims that are inherent in the testing, production, marketing and sale of human diagnostic and therapeutic products. While we believe that we are reasonably insured against these risks, there can be no assurance that we will be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. A product liability claim in excess of our insurance coverage or a recall of one of our products would have to be paid out of our cash reserves.
Because we receive revenues principally from life science companies, the capital spending policies of these entities have a significant effect on the demand for our products.
Our customers include clinical diagnostic, pharmaceutical, biotechnological, chemical and industrial companies, and the capital spending policies of these companies can have a significant effect on the demand for our products. These policies are based on a wide variety of factors, including governmental regulation or price controls, the resources available for purchasing research equipment, the spending priorities among various types of analytical equipment and the policies regarding capital expenditures during recessionary periods. Any decrease in capital spending by life sciences companies could cause our revenues to decline.
If third-party payors increasingly restrict payments for healthcare expenses or fail to adequately pay for multi-analyte testing, we may experience reduced sales which would hurt our business and our business prospects.
Third-party payors, such as government entities, health maintenance organizations and private insurers, are restricting payments for healthcare. These restrictions may decrease demand for our products and the price we can charge. Increasingly, Medicaid and other third-party payors are challenging the prices charged for medical services, including clinical diagnostic tests. They are also attempting to contain costs by limiting coverage and the reimbursement level of tests and other healthcare products. Without adequate coverage and reimbursement, consumer demand for tests will decrease. Decreased demand could cause sales of our products, and sales and services by our strategic partners, to fall. In addition, decreased demand could place pressure on us or our strategic partners to lower prices on these products or services, resulting in lower margins. Reduced sales or margins by us or our strategic partners would hurt our business, profitability and business prospects.
Our limited operating history and reliance on strategic partners to market our products makes forecasting difficult.
Because of our limited operating history, it is difficult to accurately forecast future operating results. Our operating expenses are largely based on anticipated revenue trends and a high percentage of our expenses are, and will continue to be, fixed in the short-term. As a result, if we do not achieve our expected revenues, our operating results will be below our expectations. The level of our revenues will depend upon the rate and timing of the adoption of our technology as a method to perform bioassays. Due to our limited operating history, predicting this timing and rate of adoption is difficult.
In addition, we anticipate that a large percentage of future sales of our products, and products incorporating our technology, will be made by our strategic partners. For the following reasons, estimating the timing and amount of sales of these products that may be made by our strategic partners is particularly difficult:
. We have no control over the timing or extent of product development, marketing or sale of our products by our strategic partners.
. Our strategic partners are not committed to minimum purchase commitments and we do not have control over the incentives provided by our strategic partners to their sales personnel.
. A significant number of our strategic partners intend to produce clinical diagnostic applications that may need to be approved by the United States FDA.
. Certain strategic partners may have unique requirements for their applications and systems. Assisting the various strategic partners may strain our research and development and manufacturing resources. To the extent that we are not able to timely assist our strategic partners, the commercialization of their products will likely be delayed.
We have and expect to maintain a limited marketing, sales and distribution staff. As a result, if our strategic partners fail to achieve projected levels of sales, we will likely not achieve our estimated operating results.
Our operating results may fluctuate significantly from quarter to quarter.
The sale of bioassay testing devices typically involves a significant technical evaluation and commitment of capital by customers. Accordingly, the sales cycle associated with our products typically is lengthy and subject to a number of significant risks, including customers' budgetary constraints and internal acceptance reviews that are beyond our control. Due to this lengthy and unpredictable sales cycle, our operating results could fluctuate significantly from quarter to quarter.
The vast majority of our system sales are made to our strategic partners. Our partners typically purchase instruments in three phases during their commercialization cycle; first, instruments necessary to support internal assay development; second, instruments for sales force demonstrations; and finally, instruments for resale to their customers. As a result, most of our system placements are highly dependent on the commercialization timetables of our strategic partners, and can fluctuate from quarter to quarter as our strategic partners move from phase to phase. We expect this trend to continue for the foreseeable future.
Our operating results may be affected by current economic and political conditions.
On September 11, 2001, the United States was the target of unprecedented terrorist attacks. These attacks have created many economic and political uncertainties, some of which may adversely affect our business and revenues. While we do not believe that the attacks had an adverse effect on our operations during the third quarter, the long-term effects of the attacks on our business and revenues are unknown. The potential for future terrorist attacks, the national and international responses to terrorist attacks, and other acts of war or hostility have created many economic and political uncertainties, which also could adversely affect our business and revenues in the short or long term in ways that cannot presently be predicted.
Our stock price has been and is likely to continue to be volatile.
The trading price of our common stock has been and is likely to continue to be highly volatile and subject to wide fluctuations in price. This volatility is in response to various factors, many of which are beyond our control, including:
. general economic conditions and interest rates;
. instability in the United States and other financial markets as a result of the terrorist attacks on September 11, 2001 and the possibility of armed hostilities or further acts of terrorism in the United States or elsewhere;
. actual or anticipated variations in quarterly operating results from historical results or estimates of results prepared by us or by securities analysts;
. announcements of technological innovations by us or our competitors;
. new products or services introduced or announced by us or our competitors;
. changes in financial estimates by us or by securities analysts;
. conditions or trends in the life science, biotechnology and pharmaceutical industries;
. announcements by us of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
. additions or departures of key personnel; and
. sales of our common stock.
In addition, the stock market in general, and The Nasdaq National Market and the market for technology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, there has been particular volatility in the market prices of securities of life sciences companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs, potential liabilities and the diversion of management's attention and resources.
Our directors and executive officers have substantial control over Luminex, which could delay or prevent a merger or other change in control transaction.
Our directors and executive officers beneficially owned approximately 43% of our outstanding common stock as of November 6, 2001. These persons will be able to exercise significant influence over all matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions. This concentration of ownership may also delay or prevent a change in control of the company even if beneficial to our stockholders.
Anti-takeover provisions in our charter and bylaws and Delaware law and our stockholder rights plan could make a third-party acquisition of us difficult.
Our certificate of incorporation, bylaws and stockholder rights plan contain provisions that could make it more difficult for a third party to acquire us, even if doing so would be beneficial to our stockholders. These provisions could limit the price that investors might be willing to pay in the future for shares of our common stock. We are also subject to certain provisions of Delaware law that could delay, deter or prevent a change in control of us.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our interest income is sensitive to changes in the general level of U.S. interest rates, particularly since the majority of our investments are in short- term instruments held to maturity. Due to the nature of our short-term investments, we have concluded that we are not subject to material market risk exposure.
PART II
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
The exhibits listed in the accompanying Exhibit Index are filed as part of this Quarterly Report on Form 10-Q.
(b) Reports on Form 8-K:
The Company did not file any report on Form 8-K during the three months ended September 30, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 9, 2001.
LUMINEX CORPORATION
By: /s/ Frank J. Reeves ----------------------------------------- Frank J. Reeves Executive Vice President, Treasurer and Chief Financial Officer (Principal Financial Officer) |
EXHIBIT INDEX
Exhibit Number Description Of Document ------ ----------------------- 10.18 Lease Agreement dated October 19, 2001 between Aetna Life Insurance Company and Luminex Corporation. 23.10 Acknowledgement of Independent Accountants. |
EXHIBIT 10.18
LEASE AGREEMENT
Between
AETNA LIFE INSURANCE COMPANY,
as Landlord,
and
LUMINEX CORPORATION,
as Tenant,
Covering approximately 98,158 gross square feet of the Buildings known (or to be known) as
McNeil 3, McNeil 4, and McNeil 5
located at
12109-12201, 12212, and 12112 Technology Boulevard
Austin, Texas, 78727
STANDARD INDUSTRIAL LEASE AGREEMENT
TRAMMELL CROW COMPANY - (AUS/91)
Approximately 98,158 gross square feet
Austin, Texas 78727
(__________________)
LEASE AGREEMENT
THIS LEASE AGREEMENT (this "Lease") is made and entered into by and between Aetna Life Insurance Company, by UBS Realty Investors LLC, its investment advisor and agent, hereinafter referred to as "Landlord," and Luminex Corporation, hereinafter referred to as "Tenant."
1. PREMISES, TERM, AND TENANT IMPROVEMENTS.
i. Tenant is currently leasing from Landlord approximately 51,189 square
feet located in three buildings, with differing termination dates, as follows:
(a) 18,330 square feet in McNeil 3, Suite 130 (the "Current McNeil 3 Premises")
terminating on May 31, 2003; (b) 12,737 square feet in McNeil 4, Suites I, J and
K (the "Current McNeil 4 Premises") terminating on March 31, 2002; and (c)
20,122 square feet in McNeil 5, Suite 200 (the "Current McNeil 5 Premises")
terminating on March 31, 2002, all of which current premises are sometimes
referred to collectively herein as the "Current Premises". In consideration of
the mutual obligations of Landlord and Tenant set forth herein, and in
conjunction with the simultaneous termination of the existing lease for the
Current Premises and its replacement herewith, Landlord leases to Tenant, and
Tenant hereby leases from Landlord, the Current Premises, as the Current
Premises are more particularly described or depicted on Exhibit "A" attached
hereto and incorporated herein by reference, to have and to hold, subject to the
terms, covenants and conditions in this Lease.
ii. Pursuant to Exhibit "B" (Expansion Space) attached hereto and incorporated herein by reference, Tenant will lease from Landlord, and Landlord will lease to Tenant, additional premises as expansion space as follows: (a) 22,713 square feet in McNeil 4 (the "McNeil 4 Expansion Space"); and (b) 24,256 square feet in McNeil 5 (the "McNeil 5 Expansion Space"), all of which additional premises are sometimes referred to collectively herein as the "Expansion Space"), and all of which Expansion Space is more particularly described or depicted on Exhibit "A" attached hereto and incorporated herein by reference.
iii. Unless otherwise indicated by the reference, all references herein to the "Premises" shall mean all of the Current Premises and the Expansion Space in the aggregate. The Premises, as more particularly described elsewhere herein, are in buildings known as McNeil 3, located at 12109-12201 Technology Boulevard, McNeil 4, located at 12212 Technology Boulevard, and McNeil 5, located at 12112 Technology Boulevard, all in Austin, Travis County, Texas.
iv. Landlord represents to Tenant that the Current Premises and the Land (hereinafter defined) do not presently violate in any material respects or give rise to liability under applicable laws or restrictive covenants or encumbrances relating to the Current Premises, and that on the applicable Commencement Date, the Expansion Space and the use thereof contemplated by this Lease will comply in all material respects with and not give rise to liability under applicable laws and any such restrictive covenants or encumbrances. Within thirty (30) days following the date hereof, Landlord shall (a) inspect and treat the Current Premises for termites (if necessary), and (b) survey the Current Premises for asbestos in accordance with City of Austin Ordinance No. 01329-49.
i. The Commencement Date for the Current Premises shall be the date hereof. The Commencement Date (a) for the McNeil 4 Expansion Space is anticipated to be November 1, 2002 (subject to adjustment pursuant to Exhibit B attached hereto), provided Landlord shall use reasonable efforts to make such McNeil 4 Expansion Space available to Tenant prior to such date, and (b) for the McNeil 5 Expansion Space is anticipated to be October 1, 2002 (subject to adjustment pursuant to Exhibit B attached hereto). Unless otherwise specifically indicated in the reference, all references herein to the "Commencement Date" shall apply to each portion of the Premises, and the parties' rights and obligations in connection therewith, according to the particular commencement date applicable to each such portion of the Premises. Except as may expressly be provided otherwise in this Lease, including any exhibit hereto, regarding "Tenant Improvements" (as defined below), Tenant acknowledges that as of the Commencement Date (I) it has inspected and accepts the Premises in their "as is" condition, (II) the buildings and improvements comprising the same are suitable for the purpose for which the Premises are leased, (III) the Premises are in good and satisfactory condition, and (IV) no representations as to the repair of the Premises nor promises to alter, remodel or improve the Premises have been made by Landlord.
ii. The term of this Lease shall end on July 31, 2010 for all of the Premises, unless renewed and extended, or otherwise amended, as hereinafter provided for. The "Term" of this Lease means the period between the Commencement Date and the termination date hereof, and includes any Renewal Term (as defined in Exhibit "C" attached hereto).
2. BASE RENT, SECURITY DEPOSIT AND TENANT COSTS.
For the Current McNeil 3 Premises (18,330 square feet)
-------------------------------------------------------------------------------------------- Months Base Rental Rate PSF/Mo. Total Monthly Rent -------------------------------------------------------------------------------------------- Date hereof - October 31, 2001 $0.80 Already Paid -------------------------------------------------------------------------------------------- November 1, 2001 - November 30, 2001 $0.00 $ 0.00 -------------------------------------------------------------------------------------------- December 1, 2001 - June 30, 2003 $0.80 $14,664.00 -------------------------------------------------------------------------------------------- July 1, 2003 - April 30, 2005 $0.85 $15,580.50 -------------------------------------------------------------------------------------------- |
For the Current McNeil 4 Premises (12,737 square feet)
-------------------------------------------------------------------------------------------- Months Base Rental Rate PSF/Mo. Total Monthly Rent -------------------------------------------------------------------------------------------- Date hereof - October 31, 2001 $0.75 Already Paid -------------------------------------------------------------------------------------------- November 1, 2001 - November 30, 2001 $0.00 $ 0.00 -------------------------------------------------------------------------------------------- December 1, 2001 - April 30, 2002 $0.80 $10,189.60 -------------------------------------------------------------------------------------------- May 1, 2002 - April 30, 2005 $0.85 $10,826.45 -------------------------------------------------------------------------------------------- |
For the McNeil 4 Expansion Space (22,713 square feet)
-------------------------------------------------------------------------------------------- Months Base Rental Rate PSF/Mo. Total Monthly Rent -------------------------------------------------------------------------------------------- November 1, 2002 -November 30, 2002 $0.00 $ 0.00 -------------------------------------------------------------------------------------------- December 1, 2002 - April 30, 2005 $0.85 19,306.05 -------------------------------------------------------------------------------------------- |
For the Current McNeil 5 Premises (20,122 square feet)
-------------------------------------------------------------------------------------------- Months Base Rental Rate PSF/Mo. Total Monthly Rent -------------------------------------------------------------------------------------------- Date hereof - October 31, 2001 $0.75 Already Paid -------------------------------------------------------------------------------------------- November 1, 2001 - November 30, 2001 $0.00 $ 0.00 -------------------------------------------------------------------------------------------- December 1, 2001 - April 30, 2002 $0.75 $15,091.50 -------------------------------------------------------------------------------------------- May 1, 2002 - April 30, 2005 $0.85 $17,103.70 -------------------------------------------------------------------------------------------- |
For the McNeil 5 Expansion Space (24,256 square feet)
-------------------------------------------------------------------------------------------- Months Base Rental Rate PSF/Mo. Total Monthly Rent -------------------------------------------------------------------------------------------- October 1, 2002 - October 31, 2002 $0.00 $ 0.00 -------------------------------------------------------------------------------------------- November 1, 2002 -April 30, 2005 $0.85 $20,617.60 -------------------------------------------------------------------------------------------- |
For all of the Premises beginning May 1, 2005
-------------------------------------------------------------------------------------------- Months Base Rental Rate PSF/Mo. Total Monthly Rent -------------------------------------------------------------------------------------------- May 1, 2005 - April 30, 2007 $0.89 $87,360.62 -------------------------------------------------------------------------------------------- May 1, 2007 - April 30, 2009 $0.92 $90,305.36 -------------------------------------------------------------------------------------------- May 1, 2009 - July 31, 2010 $0.96 $94,231.68 -------------------------------------------------------------------------------------------- |
per month during the Term. One monthly installment of base rent, plus the other monthly charges set forth in Paragraph 2C below, shall be due and payable on the Commencement Date, and a like monthly installment shall be due and payable, according to the rent schedule above, on or before the first day of each calendar month succeeding the Commencement Date, except that all payments due hereunder for any fractional calendar month shall be prorated. Tenant shall combine its payments of rent hereunder for each of the component areas of the Premises into one monthly payment.
Building or Project (provided, however, the cost of any alteration made to the Building or Project because of a change in law that becomes effective after the Commencement Date may be capitalized and Landlord's cost of operation and maintenance of the Project may include a factor each year equal to the amount necessary to amortize such capitalized alteration over their useful lives on a straight-line basis). During each month of the Term, on the same day that rent is due hereunder, Tenant shall deposit in escrow with Landlord an amount equal to one-twelfth (1/12) of the estimated amount of Tenant's Proportionate Share of the Tenant Costs. Tenant authorizes Landlord to use the funds deposited with Landlord under this Paragraph 2C to pay such Tenant Costs. The initial monthly escrow payments are based upon the estimated amounts for the year in question and shall be increased or decreased in good faith annually to reflect the projected actual amount of all Tenant Costs. If the Tenant's total escrow deposits for any calendar year are less than Tenant's actual Proportionate Share of the Tenant Costs for such calendar year, Tenant shall pay the difference to Landlord within ten (10) days after demand. If the total escrow deposits of Tenant for any calendar year are more than Tenant's actual Proportionate Share of the Tenant Costs for such calendar year, Landlord shall retain such excess and credit it against Tenant's escrow deposits next maturing after such determination.
3. TAXES
4. LANDLORD'S REPAIRS AND MAINTENANCE.
5. TENANT'S REPAIRS.
6. ALTERATIONS. Except as otherwise specifically provided in this Lease and
minor cosmetic changes to the interior of the Premises, Tenant shall not make
any alterations, additions or improvements to the Premises without the prior
written consent of Landlord, which consent shall not be unreasonably withheld,
conditioned or delayed. Landlord shall not be required to notify Tenant of
whether it consents to any alteration, addition or improvement until it (a) has
received plans and specifications in a CAD disk format (or other format which is
the industry standard at the time of the alteration) therefor which are
sufficiently detailed to allow construction of the work depicted thereon to be
performed in a good and workmanlike manner, and (b) has had a period of five
business days to review them. Landlord's approval of any plans and
specifications shall not be a representation that the plans or the work depicted
thereon will comply with law or be adequate for any purpose, but shall merely be
Landlord's consent to performance of the work. Upon completion of any material
alteration, addition, or improvement, Tenant shall deliver to Landlord accurate,
reproducible as-built plans therefor in a CAD disk format (or other format which
is the industry standard at the time of the alteration); provided that Tenant is
not required to provide such plans in a CAD disk format (or other format which
is the industry standard at the time of the alteration) for alterations,
addition, or improvements that cost less than $10,000.00 in the aggregate to
construct; provided further, however, that in any event, and regardless of cost,
if the alteration, addition or improvement will affect the Building's structure,
HVAC system, or mechanical, electrical, or plumbing systems, then the plans and
specifications therefor must be prepared by a licensed engineer reasonably
acceptable to Landlord and provided to Landlord in a CAD disk format (or other
format which is the industry standard at the time of the alteration). Tenant
may erect shelves, bins, machinery and trade fixtures provided that such items
(1) do not alter the basic character of the Premises or the Building; (2) do not
overload or damage the same; and (3) may be removed without damage to the
Premises. Unless Landlord specifies in writing otherwise, all alterations,
additions, and improvements, but not Tenant's trade fixtures, shall be
Landlord's property when installed in the Premises. All shelves, bins,
machinery and trade fixtures installed by Tenant shall be removed on or before
the earlier to occur of the day of termination or expiration of this Lease or
vacating the Premises, at which time Tenant shall restore the Premises to their
original condition, reasonable wear and tear excepted. All work performed by
Tenant in the Premises (including that relating to the installations, repair
replacement, or removal of any item) shall be performed in accordance with all
applicable governmental laws, ordinances, regulations, and with Landlord's
reasonable specifications and requirements, in a good and workmanlike manner,
and so as not to damage or alter the Building's structure or the Premises.
Tenant shall be responsible for compliance with The Americans With Disabilities
Act of 1990 (as amended, the "Act") as the Act effects the Premises, including
the entrance doors to the Premises located in exterior walls of a Building which
are modified by Tenant in connection with its renovation of the Premises or the
outside of a Building; Landlord shall be responsible for compliance with the Act
as it effects the Project and are not the responsibility of Tenant as provided
in this sentence. Notwithstanding the foregoing, Landlord shall bear all
expenses of altering the applicable portion of the Expansion Space to comply
with the Act as of the applicable Commencement Date based on the density ratios
of comparable space in the Current Premises.
7. SIGNS. Any signage Tenant desires for the Premises shall be subject to Landlord's written approval (which approval shall not be unreasonably withheld), and shall be submitted to Landlord prior to Tenant's installation of such signage. Tenant shall repair, paint, and/or replace the Building fascia surface to which its signs are attached upon Tenant's vacating the Premises or the removal or alteration of its signage. Tenant shall not, without Landlord's prior written consent (which consent shall not be unreasonably withheld), (i) make any changes to the exterior of the Premises, such as painting; (ii) install any exterior lights, decorations, balloons, flags, pennants or banners; or (iii) erect or install any signs, windows or door lettering, placards, decorations or advertising media of any type which can be viewed from the exterior of the Premises. All signs, decorations, advertising media, blinds, draperies and other window treatment or bars or other security installations visible from outside the Premises shall conform in all respects to the criteria established by Landlord or shall be otherwise subject to Landlord's prior written consent, which consent shall not be unreasonably withheld. Provided that Landlord and Tenant must first mutually agree as to the location and appearance of such monument signage (such agreement by Landlord not to be unreasonably withheld), and subject to applicable governmental regulations, Tenant may install up to three (3) monument signs at the Project at Tenant's sole cost and expense (including, without limitation, permitting, design, and construction costs). Tenant shall keep any such monument signs in good maintenance and repair during the Term, and after the Term such monument sign structures shall be the property of Landlord, provided that Tenant shall remove its sign panels and/or fascia at its sole cost and expense prior to expiration of the Term.
8. UTILITIES. Tenant shall pay directly to the utility provider all electricity and telephone charges used at the Premises, together with any taxes, penalties, surcharges, maintenance charges (except to the extent Landlord is obligated to maintain the Utility Infrastructure), and the like pertaining thereto. Tenant shall obtain telephone and computer line service to the Premises. Except for electricity and telephone service, Tenant's use of all utilities shall be part of Tenant's Costs; provided, however, if Tenant's use of any utility exceeds building-standard service, Landlord may, at Tenant's expense, separately meter and bill Tenant as a portion of Tenant's Costs (but at the full cost, not Tenant's Proportionate Share thereof) directly for its use of any such utility service, in which case, the amount separately billed to Tenant for above building-standard utility service shall not be duplicated in Tenant's obligation to pay additional rent under Paragraph 2C. If Landlord fails to maintain the Utility Infrastructure as provided in Paragraph 4A such that Tenant's business in the Premises is materially and adversely affected (for purposes of this Section 8, "Landlord's Utility Failure"), Tenant shall notify Landlord of Landlord's Utility Failure. If Landlord's Utility Failure continues for a period of three (3) consecutive business days following Tenant's notice to Landlord, then Tenant shall thereafter be entitled to an equitable abatement of Rent until such failure is cured. If Landlord commences cure of Landlord's Utility Failure within three (3) business days after Tenant's notice, and thereafter diligently pursues cure, then beginning with the sixth (6th) consecutive business day of Landlord's Utility Failure, Tenant shall be entitled to a day of Rent abatement for that portion of the Premises materially and adversely affected by Landlord's Utility Failure for each day that such failure continues. If Landlord does not timely commence cure, and Landlord's Utility Failure continues for a period of thirty (30) consecutive business days following Tenant's notice, Tenant may terminate this Lease by delivering written notice of such termination to Landlord.
9. INSURANCE.
explosive or highly inflammable, except for any such product, material, or merchandise that is incidental to Tenant's business and reasonably necessary to be kept in the Premises in the ordinary course of Tenant's business). If any increase in the cost of any insurance on the Premises or any Building is caused by Tenant's use of the Premises or because Tenant vacates the Premises, then Tenant shall pay the amount of such increase to Landlord upon demand therefor.
10. FIRE AND CASUALTY DAMAGE.
11. LIABILITY AND INDEMNIFICATION.
"Losses" means the following, to the extent (but only to the extent)
resulting from, arising out of or in connection with events or
circumstances (including the condition of the Project) that occurred or
existed or may hereafter occur or exist on or before the Loss Cutoff Date:
any and all losses, liabilities, damages (whether actual, consequential,
punitive or otherwise denominated), demands, claims, administrative or
legal proceedings, actions, judgments, causes of action, assessments,
fines, penalties, costs and expenses (including reasonable attorneys' fees
and the reasonable fees of outside accountants and environmental
consultants), of any and every kind or character, foreseeable and
unforeseeable, liquidated and contingent, proximate and remote.
"Loss Cutoff Date" means the latest of the dates upon which (i) this Lease terminates or expires, (ii) Tenant surrenders possession of the Premises (even if after the termination or expiration of the Term of this Lease), or (iii) Tenant ceases to have any leasehold interest in the Project under this Lease (with the understanding that if, at any time, one of the three listed events has not occurred, then the Loss Cutoff Date shall not have occurred).
"Indemnified Party" means a party entitled to indemnification from the Indemnifying Party under this paragraph 11.
"Indemnifying Party" means a party obligated to indemnify an Indemnified Party under this paragraph 11.
this Lease to protect against the above occurrences if Tenant desires additional protection or coverage for such risks. Tenant shall give Landlord prompt notice of any criminal or suspicious conduct within or about the Premises, the Buildings or the Project and/or any personal injury or property damage caused thereby. Landlord may, but is not obligated to, enter into agreements with third parties for the provision, monitoring, maintenance and repair of any courtesy patrols or similar services or fire protective systems and equipment and, to the extent same is provided at Landlord's sole discretion, Landlord shall not be liable to Tenant for any damages, costs or expenses which occur for any reason in the event any such system or equipment is not properly installed, monitored or maintained or any such services are not properly provided. Landlord shall use reasonable diligence in the maintenance of existing lighting, if any, in the parking garage or parking areas servicing the Premises, and Landlord shall not be responsible for additional lighting or any security measures in the Project, the Premises, any parking garage or other parking areas.
12. USE. The Premises shall be used only for those uses permitted by
applicable law, provided, however, that (i) outside storage, including without
limitation storage of trucks and other vehicles, (ii) the conduct of a sexually
oriented business, or (iii) any residential uses are prohibited without
Landlord's prior written consent. Without limiting any obligations of Tenant
hereunder, including, without limitation, Tenant's compliance obligations under
Section 6, Tenant shall comply with all governmental laws, ordinances and
regulations applicable to Tenant's particular use of the Premises and shall
promptly comply with all governmental orders and directives for the correction,
prevention and abatement of nuisances in, upon or connected with the Premises,
all at Tenant's sole expense. Tenant shall not permit any objectionable or
unpleasant odors, smoke, dust, gas, noise or vibrations to emanate from the
Premises, nor take any other action that would constitute a nuisance or would
disturb, unreasonably interfere with or endanger Landlord or any other lessees
of the Building or the Project.
13. HAZARDOUS WASTE.
"Environmental Law" shall mean any federal, state or local statute, ordinance, regulation or other law of a governmental or quasi-governmental authority relating to pollution or protection of the environment or the regulation of the storage or handling of Hazardous Substances.
"Environmental Reports" shall mean a Phase I Environmental Site Assessment and/or Phase II Environmental Site Assessment of the Project prepared for Tenant including any updates thereto.
"Hazardous Substances" shall mean pollutants, contaminants, toxic or hazardous wastes, radioactive materials or any other substances, the use and/or the removal of which is required or the use of which is restricted, prohibited or penalized by any Environmental Law.
"Permitted Activities" shall mean those activities that are part of the ordinary course of Tenant's business activities.
"Permitted Materials" shall mean those materials that are used in the ordinary course of Tenant's business.
"Tenant's Group" shall mean Tenant or Tenant's employees, agents, contractors, or invitees (excluding Landlord or Landlord's employees, agents, contractors, and invitees).
costs associated with said work. If at any time during or after the Term, the Premises are found to be contaminated with Hazardous Substances in violation with applicable Environmental Law as a result of the Tenant Group's actions or omissions in violation of this Lease, Tenant shall diligently institute proper and thorough clean-up procedures, at Tenant's sole cost. If at any time during or after the Term, the Premises are found to be contaminated with Hazardous Substances in violation with applicable Environmental Law which are not the result of the Tenant Group's actions or omissions in violation of this Lease, Landlord shall diligently institute proper and thorough clean-up procedures, at Landlord's sole cost.
14. INSPECTION. Landlord's agents and representatives shall have the right to enter the Premises at any reasonable time during business hours (or at any time in case of emergency) (i) to inspect the Premises, (ii) to make such repairs as may be required or permitted pursuant to this Lease, and/or (iii) during the last six (6) months of the Term, for the purpose of showing the Premises. In addition, Landlord shall have the right to erect a suitable sign on the Premises stating the Premises are available for lease during the last twelve (12) months of the Term.
15. ASSIGNMENT AND SUBLETTING. Tenant shall not have the right to sublet, assign or otherwise transfer or encumber this Lease, or any interest therein, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed. (Notwithstanding the foregoing, Landlord hereby consents to the sublease to any entity owned or controlled by Mark Chandler of no more than twenty percent (20%) of the then total square footage of the Premises for which Tenant is then obligated to pay Rent hereunder.) Any attempted assignment, subletting, transfer or encumbrance by Tenant in violation of the terms and covenants of this paragraph shall be void. Any assignee, sublessee or transferee of Tenant's interest in this Lease (all such assignees, sublessees and transferees being hereinafter referred to as "Transferees"), by assuming Tenant's obligations hereunder, shall assume liability to Landlord for all amounts paid to persons other than Landlord by such Transferees to which Landlord is entitled or is otherwise in contravention of this Paragraph 15. No assignment, subletting or other transfer, whether or not consented to by Landlord or permitted hereunder, shall relieve Tenant of its liability under this Lease. If an Event of Default occurs while the Premises or any part thereof are assigned or sublet, then Landlord, in addition to any other remedies herein provided or provided by law, may collect directly from such Transferee all rents payable to the Tenant and apply such rent against any sums due Landlord hereunder. No such collection shall be construed to constitute a novation or a release of Tenant from the further performance of Tenant's obligations hereunder. If Landlord consents to any subletting or assignment by Tenant as hereinabove provided and any category of rent subsequently received by Tenant under any such sublease is in excess of the same category of rent payable under this Lease, or any additional consideration is paid to Tenant by the assignee under any such assignment, then Landlord may, at its option, declare such excess rents under any sublease or such additional consideration for any assignment to be due and payable by Tenant to Landlord as additional rent hereunder. The mortgage, pledge, hypothecation or other encumbrance of or grant of a security interest by Tenant in this Lease shall additionally constitute an assignment of this Lease by Tenant for the purposes of this Paragraph 15. Provided the assignment of this Lease is to an entity (a) in which or with which Tenant, or its successors or assigns, is merged or consolidated, (b) acquiring all or substantially all of Tenant's assets, or (c) acquiring all or substantially all of Tenant's stock, so long as Tenant's obligations hereunder are assumed by the new entity in the case of a merger/consolidation or asset acquisition, such assignment shall not require the consent of Landlord under this Lease, provided, however, that Tenant shall in all instances give Landlord prompt, written notice of all assignments, which notice shall include the name and address of the assignee.
16. CONDEMNATION. If more than fifty percent (50%) of the Premises in any Building is taken for any public or quasi-public use under governmental law, ordinance or regulation, or by right of eminent domain or private purchase in lieu thereof, and the taking prevents or materially interferes with the use of the remainder of the Premises for the purpose for which they were leased to Tenant, then Tenant may, within thirty (30) days of the date of such taking, terminate this Lease upon written notice to Landlord as to the Premises in that Building and the rent shall be abated during the unexpired portion of this Lease, effective on the date of such taking; provided, however, that if Tenant does not provide such notice to Landlord within thirty (30) days of taking, then Tenant shall be conclusively deemed not to have terminated this Lease. If less than fifty percent (50%) of the Premises in any Building is taken for any public or quasi-public use under any governmental law, ordinance or regulation, or by right of eminent domain or private purchase in lieu thereof, or if the taking does not prevent or materially interfere with the use of the remainder of the Premises for the purpose for which they were leased to Tenant, then (a) this Lease shall not terminate, and (b) following the condemnation, Landlord shall utilize the condemnation proceeds to restore the Building to substantially the same condition, to the extent possible, but the rent payable hereunder during the unexpired portion of this Lease shall be reduced to such extent as may be fair and reasonable under all of the circumstances. All compensation awarded in connection with or as a result of any of the foregoing proceedings shall be the property of Landlord, and Tenant hereby assigns any interest in any such award to Landlord; provided, however, Landlord shall have no interest in any award made to Tenant for loss of business or goodwill or for the taking of Tenant's trade fixtures and personal property, if a separate award for such items is made to Tenant.
17. HOLDING OVER. At the termination of this Lease by its expiration or otherwise, Tenant shall immediately deliver possession of the Premises to Landlord with all repairs and maintenance required herein to be performed by Tenant completed, reasonable wear, tear and casualty damage excepted. If, for any reason, Tenant retains possession of the Premises after the expiration or termination of this Lease, unless the parties hereto otherwise agree in writing, such possession shall be deemed to be a tenancy at will only, and all of the other terms and provisions of this Lease shall be applicable during such period, except that Tenant shall pay Landlord from time to time, upon demand, as rental for the period of such possession, an amount equal to the greater of (i) the market rate at the time of the holdover, or (ii) one and one-half (1 1/2) times the Base Rent in effect on the date of such termination of this Lease, computed on a daily basis for each day of such period. No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except as otherwise expressly provided. The preceding provisions of this Paragraph 17 shall not be construed as consent for Tenant to retain possession of the Premises in the absence of written consent thereto by Landlord.
18. QUIET ENJOYMENT. Landlord represents that it has the authority to enter into this Lease and that, so long as Tenant pays all amounts due hereunder and performs all other covenants and agreements herein set forth, Tenant shall peaceably and quietly have, hold and enjoy the Premises for the term hereof without hindrance or molestation from Landlord or anyone claiming by
through or under Landlord, subject to the terms and provisions of this Lease.
19. EVENTS OF DEFAULT. The following events (herein individually referred to as an "Event of Default") each shall be deemed to be a default in or breach of Tenant's obligations under this Lease:
A. Tenant shall fail to pay any installment of the rent herein reserved when due, or any other payment or reimbursement to Landlord required herein when due, and such failure shall continue for a period of ten (10) days following written notice of such failure to Tenant, provided, however, that Landlord shall only be obligated to give Tenant written notice of any monetary default twice in any twelve month period, and thereafter Tenant shall be deemed in default ten days after failure to make such payment without requirement of notice from Landlord.
B. In the event that Tenant abandons or vacates all or a substantial portion of the Premises for a period in excess of one (1) month and Tenant shall fail, at its expense, to maintain at least a minimum operation of the systems in the Premises, including, without limitation, the HVAC system, such that the Premises shall not incur damage or deteriorate as a result of the vacation. In addition to any other repair and maintenance obligations of Tenant under this Lease, Tenant shall repair, maintain, and operate such systems to the extent necessary to prevent or repair any damage to or deterioration of the Premises about which Tenant is aware or has been notified by Landlord or any other entity following a periodic visual inspection of the vacated Premises.
C. Tenant shall fail to discharge or bond around any lien placed upon the Premises in violation of Paragraph 22 hereof within twenty (20) days after Tenant receives actual notice or any other notice permitted by applicable law that any such lien or encumbrance is filed against the Premises.
D. Tenant shall fail to comply with any term, provision or covenant of
this Lease (other than those listed above in this paragraph) and shall not cure
such failure within thirty (30) days after written notice thereof from Landlord,
or if such failure is not reasonably susceptible of being cured within thirty
(30) days, Tenant shall fail to commence the curing thereof within thirty (30)
days after Landlord gives written notice to Tenant thereof, or having commenced
the curing thereof, Tenant shall fail to diligently pursue the curing of such
default to completion.
20. REMEDIES. Upon each occurrence of an Event of Default, Landlord shall have the option to pursue any one or more of the following remedies without any notice or demand:
(a) Terminate this Lease;
(b) Enter upon and take possession of the Premises without terminating this Lease;
(c) Make such payments and/or take such action and pay and/or perform whatever Tenant is obligated to pay or perform under the terms of this Lease, and Tenant agrees that Landlord shall not be liable for any damages resulting to Tenant from such action; and/or
(d) Alter all locks and other security devices at the Premises, with or without terminating this Lease, and pursue, at Landlord's option, one or more remedies pursuant to this Lease;
and in any such event Tenant shall immediately vacate the Premises, and if Tenant fails to do so, Landlord, without waiving any other remedy it may have, may enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be occupying such Premises or any part thereof, without being liable for prosecution or any claim of damages therefore. The provisions of this Lease are intended to supersede Section 93.002 of the Texas Property Code and Tenant hereby expressly waives any and all rights and remedies Tenant may have under Paragraph (g) of such Section 93.002.
of any of the terms, provisions and covenants of this Lease shall be deemed or construed to constitute a waiver of any other violation or default.
21. MORTGAGES. Tenant accepts this Lease subject and subordinate to any mortgages and/or deeds of trust at any time hereafter constituting a lien or charge upon the Premises or the improvements situated thereon or any of the Buildings or the Project, provided, however, that if the mortgagee, trustee or holder of any such mortgage or deed of trust elects to have Tenant's interest in this Lease superior to any such instrument, then by notice to Tenant from such mortgagee, trustee or holder, this Lease shall be deemed superior to such lien, whether this Lease was executed before or after said mortgage or deed of trust. Landlord represents that currently there is no mortgage or deed of trust encumbering the Premises. The provisions of this Paragraph 21 shall be self- operative, and no further instrument shall be required to effect such subordination; however, Landlord shall deliver to Tenant, and Tenant shall execute from time to time within ten days after delivery thereof to Tenant, a commercially reasonable instrument from each of Landlord's mortgages, trustees, or holders evidencing the subordination of this Lease to any such mortgage or deed of trust (and Landlord will make best efforts to cause such instrument to include a commercially reasonable non-disturbance provision in favor of Tenant). Tenant shall not terminate this Lease or pursue any other remedy available to Tenant hereunder for any default on the part of Landlord without first giving written notice by certified or registered mail, return receipt requested, to any mortgagee, trustee or holder of any such mortgage or deed of trust, the name and post office address of which Tenant has received written notice, specifying the default in reasonable detail and affording such mortgagee, trustee or holder a reasonable opportunity (but in no event less than thirty (30) days from the date of Tenant's notice of default to such mortgagee, trustee or holder, which 30-day period may overlap in whole or in part with Landlord's applicable cure period) to make performance, at its election, for and on behalf of Landlord. Notwithstanding the foregoing, in an emergency, Tenant may pursue any remedy (other than termination) for a Landlord default before giving notice of such default to Landlord of Landlord's mortgagee, trustee or holder.
22. MECHANIC'S LIENS. Tenant has no authority, express or implied, to create or place any lien or encumbrance of any kind or nature whatsoever upon, or in any manner to bind, the interest of Landlord or Tenant in the Premises. Tenant will defend, indemnify, and hold Landlord harmless from and against any and all loss, cost or expense, including without limitation attorneys' fees and court costs, based on or arising out of asserted claims or liens against the leasehold estate or against the right, title and interest of the Landlord in the Premises or under the terms of this Lease because of the actions of Tenant, its employees, agents, and contractors.
23. MISCELLANEOUS.
WARRANTY THAT THE PREMISES ARE HABITABLE OR SUITABLE FOR
ANY PARTICULAR PURPOSE. Landlord's agents and employees do not and will not
have authority to make exceptions, changes or amendments to this Lease, or
factual representations not expressly contained in this Lease. Under no
circumstances shall Landlord or Tenant be considered an agent of the other.
This Lease may not be altered, changed or amended except by an instrument in
writing signed by both parties hereto.
24. NOTICES. Each provision of this instrument or of any applicable governmental laws, ordinances, regulations and other requirements with reference to the sending, mailing or delivering of notice or the making of any payment by Landlord to Tenant or with reference to the sending, mailing or delivering of any notice or the making of any payment by Tenant to Landlord shall be deemed to be complied with when and if the following steps are taken:
(i) All rent and other payments required to be made by Tenant to Landlord hereunder shall be payable to Landlord at the address for Landlord set forth below or at such other address as Landlord may specify from time to time by written notice delivered in accordance herewith. Tenant's obligation to pay rent and any other amounts to Landlord under the terms of this Lease shall not be deemed satisfied until such rent and other amounts have been actually received by Landlord.
(ii) All payments required to be made by Landlord to Tenant hereunder shall be payable to Tenant at the address set forth below, or at such other address within the continental United States as Tenant may specify from time to time by written notice delivered in accordance herewith.
(iii) Except as expressly provided herein, any written notice, document or payment required or permitted to be delivered hereunder shall be deemed to be delivered when received by hand delivery, overnight service, facsimile (with confirmation), or the United States Mail, postage prepaid, Certified or Registered Mail, addressed to the parties hereto at the respective addresses set out below, or at such other address as they have theretofore specified by written notice delivered in accordance herewith.
25. ADDITIONAL PROVISIONS. See Exhibit "D" attached hereto and incorporated herein by reference.
26. LANDLORD'S LIEN. The statutory landlord's lien granted to Landlord pursuant to the Texas Property Code shall be subject and subordinate to any liens or security interests covering Tenant's inventory, or financed fixtures, furniture or equipment of Tenant. Further, in no event shall such landlord lien cover intellectual property, files, promissory notes, documents, contracts, instruments, records or similar property, and notwithstanding any eviction of Tenant pursuant to the terms of the Lease, Landlord will make such excluded property available to Tenant upon request.
27. TERMINATION OF LEASE FOR CURRENT PREMISES. Landlord and Tenant agree that the Lease Agreement dated August 1, 1989 (as amended, the "Original Lease") between Landlord's and Tenant's predecessors in interest covering the Current Premises is being terminated pursuant to a separate agreement between the parties.
EXECUTED BY LANDLORD, this 19th day of October, 2001.
AETNA LIFE INSURANCE COMPANY,
By UBS Realty Investors LLC, its Investment
Advisers and Agent
/s/ ------------------------------------------------ Attest/Witness By: Joseph E. Gaukler ------------------------------------------------ Title: Director ------------------------- ------------------------------------------------ Title: Address:c/o Trammell Crow Central Texas, Inc. ------------------------- ------------------------------------------------ 400 W. 15th Street, Suite 1100, Austin, TX 78701 ------------------------- ------------------------------------------------ |
EXECUTED BY TENANT, this 4th day of October, 2001.
LUMINEX CORPORATION
/s/ ------------------------------------------------ Attest/Witness By: Mark Chandler ------------------------------------------------ Title: President and CEO ------------------------- ------------------------------------------------ Title: Address: 12212 Technology Boulevard ------------------------- ------------------------------------------------ Austin, TX 78727 ------------------------- ------------------------------------------------ Attention: General Counsel ------------------------------------------------ |
Exhibit "A" - Description or Depiction of Premises, including Expansion Space Exhibit "B" - Expansion Space Exhibit "C" - Tenant Improvements Exhibit "D" - Additional Provisions Exhibit "E" - Lease Commission Agreement Exhibit "F" - Black Line Draft |
EXHIBIT "A-1"
[Intentionally left blank]
EXHIBIT "A-2"
Building: McNeil #4 Legal Description: Lot 10, McNeil Road Commercial Division SECTION 2 Address: 12212 Technology Blvd. Austin, Texas 78727 |
[Building layout inserted.]
EXHIBIT "A-3"
McNeil #5
44,378 SF
[Building layout inserted.]
Exhibit "B"
Expansion Space
A. Tenant may enter the Expansion Space commencing sixty (60) days before the anticipated Commencement Date stated in Section 1B(i) of this Lease for such Expansion Space (or, with regard to the McNeil 4 Expansion Space, before the date that Landlord anticipates it can deliver such space to Tenant after any remediation) (the "Entry Date") to construct Tenant's Improvements therein, provided that Tenant shall first deliver to Landlord evidence that the insurance required under Section 9B of this Lease has been obtained by Tenant and Tenant's contractors that will be working in such Expansion Space prior to the Commencement Date, and provided further that Tenant shall indemnify and hold Landlord and the Project harmless from and against any and all damages, costs, expenses, liens, and liability, as applicable, (including reasonable attorneys' fees) for damage to property or injury to or death of any person, or for unpaid amounts due to providers of services or materials, arising from or in connection with Tenant's construction of the Tenant Improvements. Tenant's failure to provide such evidence to Landlord shall not delay the Commencement Date for such Expansion Space. Any such entry shall be on the terms of this Lease, but no rent or Tenant Costs shall accrue during the period that Tenant so enters the Premises.
B. Not less than sixty (60) days prior to the relevant Entry Date, Landlord shall deliver to Tenant a letter setting forth such date. Landlord shall use its best efforts to make available and deliver each Expansion Space by the relevant Entry Date. In the event that the Premises are not made available and delivered to Tenant by the applicable Entry Date, the corresponding applicable Commencement Date (and commencement of the payment of rent and abatement of one months' rent, as reflected in Section 2A of this Lease) shall be adjusted forward by the same number of days as is such Entry Date, provided, however, if a Commencement Date is adjusted forward in excess of one hundred twenty (120) days from the anticipated Commencement Date as set forth in Section 1B(i) hereof, Tenant shall have the right to terminate Tenant's obligations to lease such Expansion Space upon written notice to Landlord, provided, however, that if such Expansion Space is made available and delivered to Tenant prior to the delivery of Tenant's termination notice to Landlord, then Tenant shall remain obligated to lease such Expansion Space. For purposes of this Lease, any Expansion Space is "available" on the date that such Expansion Space (a) is made available by Landlord with the shell Building in the same condition as on the Effective Date of this Lease, reasonable wear and tear excepted, (b) is in broom-clean condition, (c) has been inspected and treated for termites (if necessary), (d) has been surveyed for asbestos in accordance with City of Austin Ordinance No. 01329-49, and (e) is serviced by all utilities, including HVAC. Notwithstanding the foregoing, if any Expansion Space is available prior to its applicable Entry Date, Tenant shall not be obligated to accept and commence paying rent on such Expansion Space ahead of the schedule set out in Section 2A hereof. In no event shall any Commencement Date be delayed or adjusted forward as a result of any delay or failure to perform attributable to Tenant or any Tenant's employee, agent, contractor, or invitee.
C. Landlord and Tenant shall cooperate with each other to finalize the plans for such Expansion Space in accordance with Exhibit C attached hereto. All Expansion Space taken by Tenant shall be taken "as is" (except for the representations specifically made in this Lease), and Landlord shall have no obligation to construct any leasehold improvements therein or to make any alterations thereto.
D. Tenant shall not be required to commence paying rent on the applicable Expansion Space upon the later of (i) the relevant Commencement Date, or (ii) the Commencement Date as adjusted pursuant to Section A of this Exhibit.
E. Except as provided in this Exhibit "B", or as otherwise specifically provided in this Lease, the leasing of any Expansion Space shall be upon the same terms and conditions as the leasing of the Current Premises, and shall be upon and subject to all of the provisions of this Lease. Upon each applicable Commencement Date, and as more fully provided elsewhere in this Lease, rent will be increased as indicated for the Expansion Space, the Premises shall be deemed to include the applicable Expansion Space, and Tenant's Percentage Share of the Tenant Costs shall be increased to reflect the increased portion of the Project occupied by Tenant.
F. Tenant's obligations under this Exhibit "B" shall survive the expiration or earlier termination of this Lease.
Exhibit "C"
Tenant Improvements
2. Upon execution of the construction contract for the applicable space, Tenant shall cause the contractor to construct the relevant Tenant Improvements in a good and workmanlike manner, in accordance with the Plans and all governmental requirements and otherwise in accordance with Paragraph 6 of this Lease. Tenant may commence construction on the Current Premises as soon as all the Plans are approved by Landlord and necessary permits are received. Tenant may commence construction on any given Expansion Space after the Plans therefor are approved by Landlord and permits are obtained, but no sooner than the date that such Expansion Space is made available by Landlord to Tenant (as described in Exhibit "B").
3. Following final approval of the Plans in accordance with Paragraph 1 above, Tenant may from time to time make changes to the Plans with Landlord's prior written consent, which shall not be unreasonably withheld or delayed. If Tenant requests any such change, then Tenant shall pay all additional costs in designing and constructing the Tenant Improvement as a result of such changes.
5. Tenant may submit applications for progress payments (each, an "Application for Payment") from the Allowance, no more often than monthly during the construction. Each Application for Payment shall be for the aggregate cost of the Tenant Improvements constructed during the previous month. Concurrent with each Application for Payment, Tenant shall furnish to Landlord copies of all invoices and other documentation supporting all amounts for which reimbursement is requested in the Application for Payment, together with lien waivers executed by the contractors and subcontractors for the work done that is subject to reimbursement. Within ten (10) days after Tenant's submission of an Application for Payment to Landlord as required herein, Landlord shall make payment to Tenant of the amount requested therein. Landlord shall not charge any construction management fee with respect to the Tenant Improvements unless Landlord has actually performed construction management services in connection therewith pursuant to an agreement with Tenant or Tenant's contractor.
Exhibit "D"
Additional Provisions
A. Subject to all of the terms and conditions of this Exhibit D, including, without limitation, Paragraph D below, Landlord hereby grants to Tenant two (2) consecutive options to renew the Term of this Lease for five (5) years each (the "Renewal Term") by giving Landlord written notice of Tenant's election to renew at least at least nine (9) months prior to the expiration date of the primary Term or the first Renewal Term, as appropriate.
B. If Tenant has properly elected to renew the Term, then on or before the
commencement date of the upcoming Renewal Term, Landlord and Tenant shall
execute an amendment to this Lease extending the Term on the same terms provided
in this Lease, except that the Base Rent payable for each month during the
Renewal Term and the improvement allowance and any other concessions shall be
determined in accordance with the prevailing Market Rate as determined below.
Within fifteen (15) days after Landlord's receipt of Tenant's renewal notice,
Landlord will notify Tenant of Landlord's determination of the prevailing market
rental rate (calculated utilizing, as comparables, arm's length renewal tenant
transactions for space in comparable buildings for space of equivalent quality,
size, utility, and location) and any concessions (including allowances for
tenant finish improvements, free rent and other concessions) payable during the
renewal term (the "Market Rate"). Thereafter, Tenant shall have thirty (30)
days in which to notify Landlord whether Tenant agrees or disagrees with
Landlord's determination of the Market Rate. Upon delivery of such notice, if
Tenant agrees with Landlord's determination, this Lease shall be extended upon
the same terms and conditions of this Lease except the Base Rent payable for
each renewal term and any concessions shall be the prevailing Market Rate as
determined by Landlord, and Landlord and Tenant shall enter into an amendment of
this Lease extending the Term at the prevailing Market Rate as determined by
Landlord. If Tenant fails to timely notify Landlord of its agreement or
disagreement with Landlord's determination of the prevailing Market Rate, Tenant
shall be deemed to have agreed with Landlord's determination and this Lease
shall be extended upon the same terms and conditions of this Lease except the
Base Rent payable for each renewal term and any concessions shall be the
prevailing Market Rate as determined by Landlord, and Landlord and Tenant shall
enter into an amendment to evidence such extension. If Tenant timely notifies
Landlord that it disputes Landlord's determination of the prevailing Market
Rate, Landlord and Tenant agree to negotiate in good faith for a period of sixty
(60) days after Landlord's receipt of Tenant's notice disputing Landlord's
determination of the prevailing Market Rate. If Landlord and Tenant have not
reached an agreement with respect to the prevailing Market Rate within such
sixty (60) day period, Tenant shall be entitled to have the prevailing Market
Rate determined by real estate brokers as set forth below. If Tenant desires to
invoke its right to have the prevailing Market Rate determined by real estate
brokers, Tenant must notify Landlord within ten (10) business days after the
expiration of the sixty (60) day period referenced above (such notice, the
"Notification") and the prevailing Market Rate shall be determined in accordance
with the following paragraph. If Tenant does not timely invoke its right to
have the prevailing Market Rate determined by real estate brokers as provided
above, then this option to renew shall expire and this Lease shall terminate at
the expiration of the primary Term (or the then current Renewal Term, as
appropriate) of this Lease.
C. If Tenant timely invokes its rights under this Paragraph by providing Landlord the Notification, the following shall apply:
(i) Landlord and Tenant shall each appoint a real estate broker (who shall
not be required to be a disinterested broker) with at least five (5) years
experience who is familiar with rental values for similar properties in the
vicinity of the Project. Each party will make the appointment no later than
(10) days after Landlord's receipt of the Notification. The agreement of the
two brokers as to the prevailing Market Rate for the Renewal Term will be
binding upon Landlord and Tenant. If the two (2) brokers cannot agree upon the
prevailing Market Rate within thirty (30) days following their appointment, they
shall within ten (10) days thereafter agree upon a real estate broker (the
"Independent Broker"), who must be a disinterested, reputable, qualified real
estate broker with at least ten (10) years experience and who is familiar with
rental values for similar properties in the vicinity of the Project.
Immediately thereafter, each of the brokers will submit his best estimate of the
prevailing Market Rate for the Renewal Term (together with a written report
supporting such estimate) to the Independent Broker and such broker will choose
between the two estimates. The estimate of prevailing Market Rate chosen by the
Independent Broker as the closest to the prevailing Market Rate will be binding
upon Landlord and Tenant. Notification in writing of this estimate shall be
made to Landlord and Tenant within fifteen (15) days following the selection of
the Independent Broker.
(ii) If either Tenant or Landlord fails to appoint a broker or fails to notify the other party of such appointment within ten (10) days after receipt of notice that the prescribed time for appointing the brokers has passed, then the other party's broker will determine the prevailing Market Rate for the Renewal Term which must be reasonable within the context of the market.
(iii) If an Independent Broker must be chosen under the procedure set out above, he will be chosen on the basis of objectivity and competence, not on the basis of his relationship with the brokers or the parties to this Lease, and the brokers will be so advised, although the brokers will be instructed to attempt in good faith to agree upon the broker.
(iv) Either Landlord or Tenant may notify the broker selected by the other party to demand the submission of an estimate of the prevailing Market Rate or a choice of the Independent Broker as required under the procedure described above; and if the submission of such an estimate or choice is required but the other party's broker fails to comply with the demand within ten (10) days after receipt of such notice, then the prevailing Market Rate or choice of the Independent Broker, as the case may be, selected by the other broker (i.e., the notifying party's broker) will be binding upon the Landlord and Tenant.
(v) Landlord and Tenant shall bear the expense, if any, of the broker appointed by it, and the expense of the Independent Broker will be shared equally by Landlord and Tenant.
(vi) At such time as the prevailing Market Rate is determined, Landlord and Tenant shall enter into an amendment to this Lease evidencing the extension of the Lease Term at the prevailing Market Rate determined in accordance with the foregoing procedure. If for any reason the prevailing Market Rate has not been determined prior to the commencement of the Renewal Term, then during such Renewal Term until the prevailing Market Rate is determined in accordance with the procedure described above, Tenant shall pay Base Rent at the holdover rate as set out in Section 17 of this Lease. Later, when the prevailing Market Rate for the Renewal Term is determined, an adjustment will be made between Landlord and Tenant for any overpayment or underpayment of the Base Rent payable during the Renewal Term. Any underpayment of Base Rent for the period prior to such determination will be paid with the installment of Base Rent next due after such determination, and any overpayment of Base Rent shall be applied as an offset by Landlord against Tenant's next maturing installments of Base Rent.
D. This renewal option is subject to the conditions that: (i) on the date that Tenant gives Landlord its Notification, no uncured Tenant Event of Default exists; (ii) no more than two monetary Events of Default, or more than four non- monetary performance Events of Default regarding which Landlord has sent Tenant notice, have occurred during the Term; and (iii) with regard to the second renewal, Tenant may not exercise its option to renew for a second Renewal Term unless it has exercised its option for the first Renewal Term.
A. 14,846 square feet (Tanisys)
B. 3,711 square feet (Strategic Resources)
C. 14,475 square feet (Simplex)
D. 12,633 square feet (Austin American Technology)
E. 6,000 square feet (Amherst Technology) (the "McNeil 3 Expansion Space E")
"Expansion Space" and delivered in accordance with Exhibit B hereof. Promptly after Tenant's election to lease the McNeil 3 Expansion Space E, Landlord and Tenant shall execute and deliver to each other an amendment to this Lease setting forth (1) a description of the McNeil 3 Expansion Space E, (2) the effective date of the inclusion of the McNeil 3 Expansion Space E, and (3) the increase in Base Rent and Proportionate Share resulting from such inclusion.
Rental Rate for the McNeil 3 Expansion Space E (6,000 square feet)
Months Base Rental Rate PSF/Mo. Total Monthly Rent ------------------------------------------------------------------------------------------- July 1, 2003 - July 31, 2003 $0.00 $ 0.00 ------------------------------------------------------------------------------------------- August 1, 2003 - April 30, 2005 $0.85 $5,100.00 ------------------------------------------------------------------------------------------- |
Notwithstanding any provisions of this Lease to the contrary, Tenant may make improvements to the (a) facade of McNeil 4 and McNeil 5, (b) landscaping, and (c) common areas, all as more particularly described on the attached Schedule "D-1", provided, however, that under no circumstances may Tenant contract for or perform any work that will damage or weaken the foundation, load-bearing walls, or roof of any Building. All such work shall be done in a good and workmanlike manner, in accordance with Schedule "D-1" and all governmental requirements, and otherwise in accordance with Paragraph 6 of this Lease. If Tenant is not in default, and in accordance with the draw procedure for periodic progress payments concerning the Tenant Improvements contained within paragraph 5 of Exhibit C hereof, Landlord shall pay to Tenant a total of the lesser of (i) the actual cost of construction of such improvements, or (ii) Three Hundred Thousand and No/100 Dollars ($300,000.00), provided, however, that notwithstanding any provision of this Lease to the contrary, no portion of such amount shall be paid by Landlord to Tenant prior to July 1, 2002.
SCHEDULE "D-1"
[Diagram inserted.]
SCHEDULE "D-1"
[Diagram inserted.]
SCHEDULE "D-1"
[Diagram inserted.]
EXHIBIT "E"
This Lease Commission Agreement (this "Agreement") is made by and between Aetna Life Insurance Company, a Connecticut Corporation ("Owner") and Colliers Oxford Commercial ("Broker").
Name and Address of Tenant: Luminex 12201 Technology Blvd. 12212 Technology Blvd. 12112 Technology Blvd. Austin, TX 78727 |
5. Duplicate Registrations. If for any reason, more than one registration is (or alleged to be) in effect for Tenant, notwithstanding anything in this Agreement to the contrary, the total commission payable by Owner in respect of any Lease with Tenant shall be limited to the total Commission that would have been payable by Owner if only one registration were in effect. Unless otherwise agreed to in writing, the Commission shall be payable only to the broker who, in the judgment of Owner, was most instrumental in causing the consummation of the Lease and Owner shall promptly notify Broker upon Owner's determination of any duplicate registration of Tenant.
In the case of a cash-out commission the Owner shall (provided that Tenant is not then in default under the Lease) pay Broker such commission in two installments, the first of which shall be 50% of the total commission and shall be paid within thirty (30) days of full execution of the Lease Agreement and the remainder shall be paid within thirty (30) days of (a) occupancy of the Lease space by tenant, and if applicable (b) receipt of the first month's rental payment after any "free rent" period.
11. Miscellaneous.
a. "Base Rent" shall mean the minimum basic rental payment payable to Owner excluding deposits, taxes, insurance, and common area maintenance charges.
c. Broker agrees that the Tenant will not be shown the Owner's properties without an Owner's leasing representative present.
d. Time is of the essence.
e. All payments to be made hereunder and any notice required or permitted to be delivered hereunder shall be deemed received when sent by United States Mail, postage prepaid, addressed to Owner or Broker, as the case may be, at the address appearing under the signature of such party. A party may change its address for the purpose of payment or notice by written notice to the other party pursuant to the terms hereof.
f. The failure of Owner to insist upon strict performance or compliance with the terms and conditions of this Agreement, or the failure of Owner to avail itself of any of its rights or remedies hereunder, shall not in any way constitute or be deemed to be a waiver of estoppel in respect thereof or prevent Owner from thereafter insisting on strict compliance with the terms hereof.
g. This Agreement constitutes the sole and entire Agreement of the parties and supercedes any prior agreements (written and oral) between the parties concerning the subject matter hereof.
h. Recourse against Owner hereunder shall be limited to proceeding against Owner's interest in the Project or the proceeds of disposition of the Project and shall in no event exceed the amount of the commission plus reasonable attorney's fees.
Accepted and Agreed to this 15 day of June, 2001.
WITNESS: OWNER: Aetna Life Insurance Company, a Connecticut Corporation By: UBS Realty Investors, LLC (f/k/a Allegis Realty Investors, LLC), a Massachusetts limited liability company, its Investment Advisor and Agent /s/ ------------------- ------------------------------------------------------- By: Jim Hughes Title: Director |
WITNESS: BROKER:
Colliers Oxford Commercial
/s/ /s/ -------------------- ------------------------------------------------------- Jennifer Benton By: Fred R. Polansky Address: 2700 Via Fortuna Dr. Austin, TX 78746 License #: 0109397 Expiration Date: 1-31-03 Social Security #: 000-00-0000 |
EXHIBIT "F"
[BLACK LINE DRAFT OF LEASE AGREEMENT
AGAINST THE FIRST DISCUSSION DRAFT OF THIS LEASE]
Exhibit 23.1
Acknowledgment of Independent Accountants
To the Board of Directors of
Luminex Corporation
We are aware of the incorporation by reference in the Registration Statement (Form S-8 No. 333-46686) pertaining to the 2000 Long-Term Incentive Plan of Luminex Corporation of our reports dated April 19, 2001, July 19, 2001 and October 18, 2001 relating to the unaudited condensed consolidated interim financial statements of Luminex Corporation that are included in its Form 10-Q for the quarters ended March 31, 2001, June 30, 2001 and September 30, 2001.
/s/ Ernst & Young LLP Austin, Texas November 9, 2001 |